The Conversation (0)
Kane Biotech and the U.S. Army Institute of Surgical Research Sign Extension of Cooperative Research and Development Agreement
Jul. 31, 2018 08:41AM PST
Biotech InvestingKane Biotech (TSXV:KNE) has announced a three-year cooperative research and development agreement extension has been signed with the US Army Institute of Surgical Research in Houston, Texas. As quoted in the press release: The primary objective of this collaboration on “Treatments to Prevent Biofilm Formation for Promoting Wound Healing” is to develop an antibiofilm-antimicrobial wound …
Kane Biotech (TSXV:KNE) has announced a three-year cooperative research and development agreement extension has been signed with the US Army Institute of Surgical Research in Houston, Texas.
As quoted in the press release:
The primary objective of this collaboration on “Treatments to Prevent Biofilm Formation for Promoting Wound Healing” is to develop an antibiofilm-antimicrobial wound gel formulation and test the said gel formulation to address the needs of the United States Army Dental and Trauma Research Detachment’s (USADTRD) programs and that can be readily translated into clinical testing for improving the outcomes of wounded casualties.
The mission of USADTRD is to provide military relevant research and solutions to treat and rehabilitate craniomaxillofacial trauma and prevent infectious disease. The USADTRD’s Biofilm Impaired Wound Healing program focuses on providing algorithms to understand biofilm pathophysiology and test agents useful to treat not only dental biofilm (plaque) and combat wounds-associated biofilm infections, but also to provide antimicrobials for the control of dental plaque-associated oral infections.
Mark Ahrens-Townsend, President & CEO commented, “The extension of the CRADA with the U.S. Army is good news for Kane Biotech. Work previously completed with the USAISR and USADTRD involving Kane Biotech’s DispersinB® anti-biofilm enzyme yielded promising results. Over the past 18 months Kane Biotech has made significant advances with DispersinB® in the areas of formulation, stability and at scale manufacturing levels. We are eager to see this opportunity move forward for both Kane Biotech and the U.S. Army.”
A study published in Current Microbiology1 “… provides the in vitro evidence to support the use of a novel combination of DispersinB®antibiofilm enzyme that inhibits biofilm formation and disperses preformed biofilm, and thus making the biofilm bacteria more susceptible to a broad-spectrum KSL-W antimicrobial peptide.”